Authors:
Suraj Gujar, Nishant Singh
Download free PDF
Health and Hygiene Packaging Market Size & Share 2026-2035
Report ID: GMI13526
|
Published Date: November 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Health and Hygiene Packaging Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Health and Hygiene Packaging Market Size
The health and hygiene packaging market was valued at USD 105.77 billion in 2025, anticipated to reach USD 111.59 billion in 2026 and USD 187.73 billion by 2035, growing at a 6.0% CAGR (2026–2035).
Health and Hygiene Packaging Market Key Takeaways
Market Leader: Berry Global + Amcor led with over 4.54% market share in 2025.
Leading Players: Top 5 players in this market include Berry Global + Amcor, West Pharmaceutical Services, Gerresheimer AG, AptarGroup, Silgan Holdings, which collectively held a market share of 13.67% in 2025.
The health and hygiene packaging market is being reshaped by a mix shift toward regulated primary packaging, sterile barrier systems, and dispensing formats with higher qualification requirements. Pharmaceutical biologics, consumer hygiene demand in developing economies, and material-transition investment are supporting revenue growth, while commodity formats remain more exposed to input-cost swings and price-sensitive procurement.
GMI Analyst View
Based on our analysis of company-reported revenues and demand-channel data, we estimate that the health and hygiene packaging market reached USD 101.15 billion in 2024. We view the subsequent recovery as evidence that inventory adjustment and procurement caution were cyclical pressures rather than a break in the market's underlying pharmaceutical and hygiene demand base.
Health and Hygiene Packaging Market Trends, Growth Drivers & GMI Forecast Outlook
Demand is increasingly separating into high-specification pharmaceutical and medical formats, where qualification and sterility requirements reinforce supplier value, and consumer-oriented packaging, where sustainability investment and affordability pressures shape material selection. The forecast depends on continued biologics investment, qualified capacity additions, and manageable compliance costs.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Pharmaceutical demand has a disproportionate packaging effect because biologics and injectable therapies require validated container systems rather than interchangeable commodity formats. Vials, prefilled syringes, closures, and sterile secondary packs must satisfy material-compatibility, sterility, and traceability requirements, extending qualification cycles and raising switching costs. The FDA's approvals activity reinforces the breadth of demand entering regulated packaging supply chains [1]Hardman & Co. "2024 Pharma Statistics." hardmanandco.com.
Capacity additions also demonstrate that pharmaceutical customers are prioritizing ready-to-use and ready-to-fill systems that reduce contamination risk at fill-finish sites. SCHOTT Pharma's Lebanon expansion illustrates the investment response to this requirement, particularly for biologics and vaccine supply [5]SCHOTT Pharma / Business Wire. "Strengthening U.S. Pharmaceutical Supply: SCHOTT Pharma Inaugurates Expanded Vial Production in Lebanon, PA." morningstar.com. These conditions favor converters that combine cleanroom operations, validated quality systems, and dependable glass or polymer supply.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Input-cost exposure differs sharply by end market. Pharmaceutical customers often operate under long supply agreements and cannot readily substitute qualified materials, whereas consumer hygiene and personal care buyers can respond to cost increases through downspecification, pack redesign, or supplier negotiation. Aluminum foil remains an important pressure point for blister and sachet converters, with prices materially above earlier benchmarks [4]Flexible Packaging Europe. "Mixed picture for flexible packaging materials prices as 2024 ends." flexpack-europe.org.
European compliance requirements add capital and design burdens to that commercial tension. The PPWR establishes a broader regulatory path toward recyclable packaging, while healthcare formats retain technical and safety constraints that complicate material substitution [2]European Commission. "New rules for more sustainable and competitive packaging economy." environment.ec.europa.eu[3]Oliver Healthcare Packaging. "EU Packaging & Packaging Waste Regulation: Impact on Healthcare." oliverhcp.com. Suppliers must therefore fund compliance, testing, and material redevelopment while preserving barrier, sterility, and usability performance.
GMI Analyst View
We see the forecast as a quality-of-demand story rather than a uniform packaging expansion cycle. Qualified injectable and sterile systems should retain stronger commercial resilience because regulatory validation protects supplier positions, while consumer formats face a more difficult balance among affordability, recyclability, and brand differentiation.
Health and Hygiene Packaging Market Segment Analysis
By Application
By application, the health and hygiene packaging market is led by pharmaceutical & OTC packaging, which generated USD 40.19 billion in 2025 and is projected to account for 39.5% of the market in 2035. Its leadership reflects the breadth of solid-dose, injectable, and regulated secondary-packaging demand, with biologics increasing the importance of validated primary containers and patient-safe delivery formats.
Personal Hygiene Products generated USD 23.27 billion in 2025 and are projected to reach USD 39.42 billion by 2035. Demand is volume-led through diapers, adult incontinence products, feminine hygiene products, and wipes, with emerging-market household penetration providing the principal expansion path.
Personal Care & Hygiene Liquids are projected to reach USD 26.28 billion by 2035 and represented 14.0% of the market in 2025. Pumps, closures, bottles, and refill-oriented formats give packaging a direct role in dispensing performance, premium presentation, and sustainability claims.
Medical Devices & Healthcare packaging is projected to reach USD 24.40 billion by 2035, expanding at a 7.0% CAGR (2026–2035). Sterile barrier systems, diagnostic packaging, and combination-product formats benefit from rising procedural care, home-based treatment, and more stringent device-packaging validation.
Home Care & Toiletries generated USD 11.64 billion in 2025 and are projected to represent 9.5% of the market in 2035. Concentrated formulations, refill concepts, and cost-sensitive retail economics moderate packaging intensity despite continuing demand for cleaning and hygiene products.
Nutraceuticals & Dietary Supplements are projected to reach USD 5.63 billion by 2035 and represented 3.0% of the market in 2025. Premium supplement formats increasingly require moisture, oxygen, and tamper protection that resembles pharmaceutical packaging performance.
By Product Type
Bottles & Jars generated USD 16.92 billion in 2025 and are projected to grow at a 5.1% CAGR (2026–2035). Their broad utility across OTC, supplements, personal care, and home care supports steady demand, although flexible and dispensing-led alternatives capture selected applications.
Films & Sheets generated USD 14.81 billion in 2025 and are projected to hold 14.0% of the market in 2035. Their relevance spans blister lidding, sachets, sterile barrier formats, and hygiene substrates, making material engineering central to both barrier performance and recyclability.
Boxes & Cartons are projected to reach USD 19.52 billion by 2035 and represented 11.0% of the market in 2025. Pharmaceutical secondary packaging and fiber-based substitution in consumer applications support their role, particularly where labeling and patient information are required.
Bags & Pouches generated USD 10.58 billion in 2025 and are projected to grow at a 6.4% CAGR (2026–2035). Refill packs, unit-dose formats, and sterile pouches are broadening demand, although recycling requirements heighten the need for technically viable mono-material structures.
Blister Packs are projected to account for 8.2% of the market in 2035 and generated USD 9.52 billion in 2025. Their position in tablets and capsules remains durable because they combine dose visibility, barrier protection, and patient compliance features.
Vials & Ampoules are projected to reach USD 16.33 billion by 2035 and represented 8.0% of the market in 2025. Injectable drug production and the shift toward ready-to-use systems support demand for pharmaceutical-grade glass and specialized polymer containers.
Prefilled syringes, tubes, sachets and strips, trays, and overwrap formats serve more specialized delivery, unit-dose, protective, and sterile-barrier requirements. Their competitive significance lies in design compatibility with therapy format, automation, and patient use rather than in a single common material platform.
By Material
Plastic generated USD 44.42 billion in 2025 and is projected to account for 39.5% of the market in 2035. Its scale reflects versatility across films, bottles, caps, and specialty pharmaceutical containers, although regulation and brand commitments are progressively redirecting demand toward recyclable or lower-impact alternatives.
Paper & Paperboard generated USD 21.15 billion in 2025 and are projected to hold 20.0% of the market in 2035. Cartons remain essential in regulated secondary packaging, while coated and fiber-based structures are gaining relevance in personal care outer packaging.
Glass represented 12.0% of the market in 2025 and is projected to grow at a 6.9% CAGR (2026–2035). Its inertness, pharmaceutical acceptance, and premium positioning make it particularly important for biologics, vaccines, and high-value personal care formats.
Metal generated USD 8.46 billion in 2025 and is projected to account for 6.5% of the market in 2035. Foil continues to provide essential barrier performance in pharmaceutical applications, but aerosol cans and standalone tubes face substitution pressure in consumer categories.
Biodegradable & Sustainable materials are projected to reach USD 12.20 billion by 2035 and represented 4.0% of the market in 2025. Their advance depends on whether bio-based, compostable, and recyclable structures can meet required cost, barrier, and processing performance.
Composites & Laminates are projected to reach USD 18.77 billion by 2035 and represented 10.0% of the market in 2025. They remain important where a single substrate cannot provide the moisture, oxygen, light, or sterility protection required by pharmaceutical and medical applications.
Others, including nonwovens and spunbonded materials, are projected to reach USD 8.45 billion by 2035 and represented 4.0% of the market in 2025. These materials are closely tied to sterile procedure packs, medical devices, and protective healthcare applications.
GMI Analyst View
We expect the most defensible segment positions to remain where packaging is embedded in product performance: injectable containers, sterile barriers, and dispensing systems. In these categories, qualification time and failure risk make technical capability more consequential than low-cost conversion capacity, creating clearer separation between specialized suppliers and commodity producers.
Health and Hygiene Packaging Market Regional Analysis
North America Health and Hygiene Packaging Market Analysis
The health and hygiene packaging market in North America generated USD 31.20 billion in 2025 and is projected to hold 27.0% of global demand in 2035. The region's value concentration reflects regulated pharmaceutical manufacturing, medical-device production, and high adoption of advanced injectable and dispensing formats.
US
The US represented 90.0% of North American demand in 2025 and is projected to reach USD 45.36 billion by 2035. Domestic biologics manufacturing, FDA-regulated supply chains, and capacity investment continue to support demand for qualified primary packaging and drug-delivery components.
Canada
Canada generated USD 3.12 billion in 2025 and is projected to grow at a 5.5% CAGR (2026–2035). Generic pharmaceutical manufacturing and established personal-care consumption underpin a stable, quality-sensitive packaging market.
Europe Health and Hygiene Packaging Market Analysis
Europe represented 21.5% of global demand in 2025 and is projected to reach USD 37.55 billion by 2035. Its dense regulatory environment rewards suppliers able to manage pharmaceutical qualification, device-packaging standards, and emerging recyclability obligations.
Germany
Germany generated USD 4.09 billion in 2025 and is projected to grow at a 5.7% CAGR (2026–2035). Pharmaceutical manufacturing depth and local specialty-glass capabilities support demand for high-value primary packaging.
UK
The UK generated USD 3.64 billion in 2025 and is projected to account for 15.0% of European demand in 2035. Its independent regulatory setting preserves the importance of flexible qualification strategies for suppliers serving UK and continental customers.
France
France represented 15.0% of European demand in 2025 and is projected to grow at a 5.1% CAGR (2026–2035). Pharmaceutical production and luxury personal-care manufacturing sustain demand for both regulated and premium packaging formats.
Italy
Italy is projected to reach USD 5.26 billion by 2035 and represented 13.0% of European demand in 2025. Contract manufacturing, solid-dose packaging, and established glass production reinforce its regional relevance.
Spain
Spain generated USD 2.27 billion in 2025 and is projected to reach USD 3.76 billion by 2035. Domestic pharmaceutical production and Iberian personal-care supply chains support continued packaging investment.
Asia Pacific Health and Hygiene Packaging Market Analysis
The health and hygiene packaging market in Asia Pacific represented 37.0% of global demand in 2025 and is projected to reach USD 76.97 billion by 2035. Pharmaceutical capacity additions, consumer hygiene adoption, and increasingly sophisticated local production make the region the market's central volume and growth engine.
China
China generated USD 15.65 billion in 2025 and is projected to account for 40.0% of Asia Pacific demand in 2035. Large-scale pharmaceutical output supports broad demand for blister materials, cartons, bottles, and injectable packaging.
India
India represented 13.0% of Asia Pacific demand in 2025 and is projected to grow at a 7.8% CAGR (2026–2035). Its generic-drug scale and expanding regulated-market exports are increasing demand for GMP-aligned packaging systems.
Japan
Japan generated USD 6.26 billion in 2025 and is projected to account for 14.0% of Asia Pacific demand in 2035. Aging demographics and exacting pharmaceutical specifications support a mature but technically differentiated market.
South Korea
South Korea is projected to reach USD 6.93 billion by 2035 and represented 10.0% of Asia Pacific demand in 2025. Biologics production and K-beauty exports strengthen demand for injectable, premium dispensing, and visually differentiated formats.
Australia
Australia generated USD 1.57 billion in 2025 and is projected to reach USD 2.31 billion by 2035. Quality requirements remain high despite the market's mature structure and reliance on imported pharmaceutical packaging inputs.
Latin America Health and Hygiene Packaging Market Analysis
Latin America represented 7.0% of global demand in 2025 and is projected to grow at a 6.6% CAGR (2026–2035). Pharmaceutical localization, private-healthcare expansion, and urban consumer hygiene demand are supporting a broader packaging base.
Brazil
Brazil generated USD 3.55 billion in 2025 and is projected to account for 47.0% of Latin American demand in 2035. Its large pharmaceutical and personal-care industries make it the region's principal market for both primary and consumer packaging.
Mexico
Mexico represented 22.0% of Latin American demand in 2025 and is projected to grow at a 7.3% CAGR (2026–2035). Nearshoring and export-oriented manufacturing increase the need for packaging aligned with North American quality expectations.
Argentina
Argentina represented 10.0% of Latin American demand in 2025. Macroeconomic volatility constrains converter investment, although domestic pharmaceutical production and consumer hygiene demand preserve a meaningful long-term market base.
Middle East & Africa Health and Hygiene Packaging Market Analysis
The health and hygiene packaging market in Middle East & Africa generated USD 5.29 billion in 2025 and is projected to account for 4.5% of global demand in 2035. Healthcare infrastructure, pharmaceutical distribution hubs, and local manufacturing initiatives shape demand across a diverse regional operating environment.
UAE
The UAE represented 25.0% of Middle East & Africa demand in 2025 and is projected to reach USD 2.20 billion by 2035. Regional distribution and premium personal-care consumption support demand for compliant, differentiated packaging.
Saudi Arabia
Saudi Arabia generated USD 1.22 billion in 2025 and is projected to account for 24.5% of Middle East & Africa demand in 2035. Healthcare investment and domestic pharmaceutical-production ambitions are expanding the need for qualified packaging systems.
South Africa
South Africa represented 15.0% of Middle East & Africa demand in 2025. Its role as a distribution gateway for sub-Saharan markets supports pharmaceutical and healthcare packaging demand despite uneven regional infrastructure.
GMI Analyst View
We believe Asia Pacific requires differentiated rather than uniform investment strategies. Suppliers that align technical specifications, local sourcing, and price architecture to individual national markets will be better positioned than those relying on a single regional operating model across mature, emerging, and export-oriented pharmaceutical markets.
Health and Hygiene Packaging Market Share & Competitive Landscape
The health and hygiene packaging market share remains fragmented, with the top five players collectively accounting for 13.67% of the market in 2025. Fragmentation reflects the difficulty of serving pharmaceutical glass, flexible hygiene materials, dispensing systems, sterile medical packaging, and consumer containers through one common operating model.
Berry Global + Amcor held a 4.54% market share in 2025. The combined platform broadens exposure across flexible, healthcare, container, and closure categories, providing material-science scale and a wider geographic manufacturing footprint.
West Pharmaceutical Services held a 2.91% market share in 2025. Its position is supported by injectable packaging components and delivery systems, where customers value quality assurance, regulatory documentation, and reliable capacity. West reported Q3 2026 net sales of USD 874.5 million, with year-on-year growth and stronger proprietary-product demand, underscoring continued pharmaceutical customer investment [7]West Pharmaceutical Services. "West Reports Third-Quarter 2026 Results." investor.westpharma.com.
Gerresheimer AG held a 2.18% market share in 2025. Its pharmaceutical glass and drug-delivery focus is strengthened by portfolio rationalization, including the completed Centor transaction, which carried a combined enterprise value of approximately USD 1.7 billion with the related Primary Packaging Plastics business [6]Gerresheimer AG. "Gerresheimer Successfully Completes Sale of Centor." eqs-news.com.
AptarGroup competes through precision dispensing and drug-delivery technologies, particularly where dosing accuracy and patient usability differentiate the package from a standard closure. Silgan Holdings participates through specialized dispensing and closure systems for pharmaceutical, personal-care, and home-care customers. Other specialized competitors, including Schott Pharma, Stevanato Group, Huhtamaki, Constantia Flexibles, SGD Pharma, Oliver Healthcare Packaging, Wipak, Tekni-Plex, SteriPack Group, Klockner Pentaplast, Sealed Air, Nipro Corporation, UFlex, and TOPPAN Packaging, compete through application expertise, regional manufacturing, qualification capability, and material specialization.
Recent Industry Developments
SCHOTT Pharma inaugurated expanded vial production in Lebanon, Pennsylvania, supporting standard and ready-to-use vial capacity for biologics and vaccines. The project was supported by BARDA funding and is intended to strengthen domestic pharmaceutical supply resilience [5]SCHOTT Pharma / Business Wire. "Strengthening U.S. Pharmaceutical Supply: SCHOTT Pharma Inaugurates Expanded Vial Production in Lebanon, PA." morningstar.com.
Gerresheimer completed the sale of Centor as part of a portfolio restructuring that sharpens its focus on high-value pharmaceutical primary packaging and drug-delivery systems [6]Gerresheimer AG. "Gerresheimer Successfully Completes Sale of Centor." eqs-news.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →